GHD is an endocrine disorder characterized by the insufficient production of GH by the pituitary gland. GHD is more commonly seen in children, although it can develop during adulthood. GHD can be present from birth (congenital), or it can be secondary due to brain trauma (acquired). Generally, a child with GHD is born with normal size at birth, but has delayed rates of bone development and bone lengthening later on. Patients who acquire GHD later in life present with more generalized symptoms, such as increased abdominal fat, decreased levels of energy, and decrease in muscle mass. In young children, certain kinds of cancer treatments, such as cranial radiation, can increase the chances of developing GHD. Other clinical procedures, such as brain surgery, can increase a patient’s chances of developing GHD. GHD may be hereditary, or it may be due to fetal malformation or genetic mutations. Acquired GHD can be caused by trauma to the head or brain and more commonly by a pituitary adenoma.
In the 7MM, the diagnosed prevalent cases of GHD for all ages and both sexes will increase from 109,551 cases in 2016 to 112,450 cases in 2026 at an Annual Growth Rate (AGR) of 0.26% in the 7MM. GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of GHD in all markets except Germany and Japan. In 2016, the US made up about 48% of all diagnosed prevalent cases of GHD in the 7MM. In 2016, the 5EU made up approximately 40%, and Japan made up nearly 13% of all cases of GHD in the 7MM.
This 10-year epidemiological forecast of GHD is supported by data obtained from international GHD disease monitoring databases, country-specific government sources, as well as peer reviewed studies using market-relevant disease definitions across the 7MM. This forecast provides detailed segmentations within GHD for each market by the patient’s age, sex, and etiological classification (congenital and idiopathic in children, and idiopathic and acquired in adults), thus creating a comprehensive view of the epidemiology of GHD in the 7MM. GlobalData epidemiologists maintained consistent forecast methodology across all seven markets, thus allowing for an accurate and meaningful comparison of included parameters among them.
Reasons to buy
The GHD EpiCast series will allow you to:
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Executive Summary
2.1 Related Reports
2.2 Upcoming Reports
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.3.1 GHD in children
3.3.2 GHD in adults
3.4 Forecast Methodology
3.4.2 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for GHD (2016-2026)
3.5.1 Diagnosed Prevalent Cases of GHD
3.5.2 Age-Specific Diagnosed Prevalent Cases of GHD
3.5.3 Sex-Specific Diagnosed Prevalent Cases of GHD
3.5.4 Idiopathic and Organic GHD in Children
3.5.5 Congenital and Acquired GHD Out of Organic GHD in Children
3.5.6 Idiopathic and Acquired GHD in Adults
3.5.7 Onset Timing
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of Analysis
3.6.3 Strengths of the Analysis
4.2 About the Authors
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About GlobalData
4.4 Contact Us
Table 1: Risk Factors and Comorbidities for GHD
Table 2: Diagnosed Prevalent Cases of GHD, Men and Women, All Ages, for 2016–2026.
Figure 1: 7MM, Diagnosed Prevalent Cases of GHD, Both Sexes, All Ages, 2016 and 2026
Figure 2: Age-Standardized Diagnosed Prevalence of GHD, Men and Women, All Ages, 2016
Figure 3: Case Flow Map of GHD
Figure 4: Sources Used and Not Used for the Diagnosed Prevalent Cases of GHD in Children
Figure 5: Sources Used and Not Used in the Forecast for Diagnosed Prevalent Cases of GHD in Adults
Figure 6 Sources Used and Not Used in the Forecast for Type of GHD in Children
Figure 7 Sources Used and Not Used in the Forecast for Type of GHD in Adults
Figure 8 Sources Used and Not Used in the Forecast for Onset Timing of GHD in Adults
Figure 9: Age-Specific Diagnosed Prevalent Cases of GHD, Men and Women, All Ages, 2016.
Figure 10: Sex-Specific Diagnosed Prevalent Cases, Men, Women, All Ages, 2016
Figure 11: Diagnosed Prevalent Cases of GHD in Children Segmented into Idiopathic and Organic GHD, Boys and Girls, Ages ?18 years, 2016
Figure 12: Diagnosed Prevalent Cases of Congenital or Acquired GHD Out of Organic GHD, Boys and Girls, Ages ?18 years, 2016
Figure 13: Idiopathic and Acquired GHD in Adults, Men and Women, Ages ?19 Years, 2016.
Figure 14: Diagnosed Prevalent Cases by Onset Timing, Men and Women, Ages ?19 Years, 2016.
Make an enquiry before buying this Report
Please fill the enquiry form below.